8-K
filed March 17, 2023, 7:59 PM ET
ticker SGMO
CIK 0001001233
other material
confidence high
sentiment negative
materiality 0.85
Sangamo announces termination of Novartis and Biogen collaborations; loses milestone/royalty potential
SANGAMO THERAPEUTICS, INC
- Novartis terminated collaboration (effective June 11, 2023); Sangamo loses up to $720M in milestones and royalties.
- Biogen terminated collaboration (effective June 15, 2023); Sangamo loses up to $2.37B in milestones and royalties.
- Sangamo will explore internal development or new partners for CNS programs but faces uncertainty.
- Company expects existing cash runway of at least 12 months from Dec. 31, 2022 remains adequate despite terminations.
Key facts
Extracted from this filing and checked against the source text.
Material Agreements
SEC 8-K Item 1.01/1.02
confidence 0.9
SANGAMO THERAPEUTICS, INC terminated Collaboration and License Agreement with Novartis Institutes for BioMedical Research, Inc. (effective 2023-06-11).
- Action
- termination
- Agreement
- collaboration
- Counterparty
- Novartis Institutes for BioMedical Research, Inc.
- Effective
- 2023-06-11
Exact text from the filing
On March 13, 2023, Novartis Institutes for BioMedical Research, Inc. ("Novartis") notified Sangamo Therapeutics, Inc. ("Sangamo") of its termination for convenience, effective June 11, 2023 (the "Novartis Termination Date"), of the Collaboration and License Agreement (the "Novartis Agreement") by and between Novartis and Sangamo dated July 27, 2020
View on SEC.gov
Material Agreements
SEC 8-K Item 1.01/1.02
confidence 0.9
SANGAMO THERAPEUTICS, INC terminated Collaboration and License Agreement with Biogen MA, Inc. (effective 2023-06-15).
- Action
- termination
- Agreement
- collaboration
- Counterparty
- Biogen MA, Inc.
- Effective
- 2023-06-15
Exact text from the filing
On March 17, 2023, Biogen MA, Inc. and its affiliate, Biogen International GmbH (together, "Biogen") notified Sangamo of its termination for convenience, effective June 15, 2023 (the "Biogen Termination Date"), of the Collaboration and License Agreement (the "Biogen Agreement") by and between Biogen and Sangamo dated February 26, 2020
View on SEC.gov
This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice.
See methodology for how this pipeline works.